Accent Microcell Limited (ACCENTMIC) share price

₹617.80 on NSE as of 2026-09-04. +1.71% on the day. market cap ₹1,482 Cr. P/E 32.9. 52-week range ₹243.50 to ₹617.80.

Accent Microcell H2 FY26: Revenue Surges 51%, Massive Capacity Integration and Niche Dominance Unlocked

At a glance

Accent Microcell is currently a high-octane growth engine disguised as a chemical company. The latest data reveals a **Sales CAGR of 32% (TTM)** and a **Profit CAGR of 33% (TTM)**. This alignment of top-line and bottom-line growth is rare and indicates that the company isn't just buying growth—it’s earning it through operational efficiency.

The Curiosity of the Pivot

The company is currently pivoting its product mix. While MCC remains the bread and butter (contributing ~85% of revenue), the real excitement is in the **Unit 3 Kheda Phase 1** expansion. This unit targets premium excipients like **Croscarmellose Sodium (CCS)** and **Sodium Starch Glycolate (SSG)**. Why does this matter? Because CCS is a "rapid disintegrant" that commands pricing **3.5 times higher than MCC**.

Introduction

Accent Microcell Limited is essentially the "hidden ingredient" company. If you have taken a medicine tablet recently, there is a high probability that the **Microcrystalline Cellulose (MCC)** holding that tablet together was manufactured by AML. Established in 2012, the company has mastered the art of manufacturing 22 different grades of MCC.

The business operates out of Gujarat, with two existing units in **Pirana** and **Dahej (SEZ)**. The Dahej unit is particularly strategic, being an SEZ unit that provides significant tax benefits and caters primarily to the export market, which accounts for roughly **53% to 61%** of total revenue.

In the last 24 months, the company has transformed its balance sheet. From a closely held public limited company in 2022 to an NSE SME listing in 2023, and a Rights Issue in 2025, AML is now a well-capitalized entity. This capital is being deployed into **Unit 3 (Kheda)**, which is designed to make the company "fully integrated." Instead of buying raw materials like CMC to make CCS, they will now manufacture everything in-house.

This vertical integration is a classic move to protect margins. In an industry where "regulatory stickiness" is high—meaning pharma companies hate switching suppliers once their filing is approved—Accent is building a moat that is difficult to bridge.

Business model

Let's simplify this: Pharmaceutical companies make the active "drug." Accent Microcell makes the "stuff" that makes the drug usable.

They manufacture **Pharmaceutical Excipients**. Think of excipients as the delivery vehicle. Without MCC, a drug might not compress into a tablet, or it might not dissolve at the right speed in your stomach.

The Product Trio:

- **MCC (The Bulker):** Used as a binding and coating agent.

- **CCS (The Disintegrant):** This is the high-value product. It makes the tablet "explode" and dissolve quickly in the body.

- **Magnesium Stearate (The Lubricant):** Ensures the tablets don't stick to the machines during manufacturing.

Quarterly results, balance sheet, cash flow, ratios, shareholding and the filings themselves are on the full page for Accent Microcell Limited.